{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:58:25Z","timestamp":1791046705630,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.tube.2010.03.005","type":"journal-article","created":{"date-parts":[[2010,4,10]],"date-time":"2010-04-10T08:34:24Z","timestamp":1270888464000},"page":"177-181","source":"Crossref","is-referenced-by-count":59,"title":["The near future: Improving the activity of rifamycins and pyrazinamide"],"prefix":"10.1016","volume":"90","author":[{"given":"D.A.","family":"Mitchison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.B.","family":"Fourie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2010.03.005_bib1","first-page":"1079","article-title":"Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis","volume":"20","author":"East African\/British Medical Research Council","year":"1972","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.tube.2010.03.005_bib2","first-page":"796","article-title":"Role of individual drugs in the chemotherapy of tuberculosis","volume":"4","author":"Mitchison","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"10.1016\/j.tube.2010.03.005_bib3","first-page":"612","article-title":"Development of rifapentine: the way ahead","volume":"2","author":"Mitchison","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6 Pt 1","key":"10.1016\/j.tube.2010.03.005_bib4","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1164\/ajrccm.157.6.9707037","article-title":"Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis: initial report","volume":"157","author":"Tam","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2010.03.005_bib5","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(02)09742-8","article-title":"Once-weekly rifapentine and INH versus twice-weekly rifampin and INH in the continuation phase of therapy for drug-susceptible pulmonary tuberculosis: a prospective, randomized clinical trial among HIV-negative persons","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.tube.2010.03.005_bib6","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1128\/AAC.01474-06","article-title":"Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears","volume":"51","author":"Diacon","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.tube.2010.03.005_bib7","first-page":"3","article-title":"What is the \u2018right\u2019 dose of rifampin?","volume":"7","author":"Peloquin","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"10.1016\/j.tube.2010.03.005_bib8","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jac\/32.6.867","article-title":"The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts. A new method of drug assessment","volume":"32","author":"Sirgel","year":"1993","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.tube.2010.03.005_bib9","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1378\/chest.120.5.1520","article-title":"Utility of rifampin blood levels in the treatment and follow up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy","volume":"120","author":"Mehta","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.tube.2010.03.005_bib10","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.200905-0795OC","article-title":"Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection","author":"Zhang","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.tube.2010.03.005_bib11","first-page":"749","article-title":"Experimental antitubercular activity of rifampicin, a derivative of rifampicin SV","volume":"31","author":"Grumbach","year":"1967","journal-title":"Rev Tuberc Pneumol (Paris)"},{"issue":"1","key":"10.1016\/j.tube.2010.03.005_bib12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/0041-3879(70)90131-5","article-title":"Suitability of rifampicin for intermittent administration in the treatment of tuberculosis","volume":"51","author":"Dickinson","year":"1970","journal-title":"Tubercle"},{"issue":"5","key":"10.1016\/j.tube.2010.03.005_bib13","first-page":"437","article-title":"Single and multiple dose pharmacokinetics of rifapentine in man: part II","volume":"3","author":"Keung","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.tube.2010.03.005_bib14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1164\/rccm.200411-1557OC","article-title":"The early bactericidal activities of rifampicin and rifapentine in pulmonary tuberculosis","volume":"172","author":"Sirgel","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.tube.2010.03.005_bib15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/BF00558302","article-title":"Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects","volume":"36","author":"Lacroix","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.tube.2010.03.005_bib16","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Zhang","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"10.1016\/j.tube.2010.03.005_bib17","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jac\/dkg446","article-title":"Mode of action of pyrazinamide disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid","volume":"52","author":"Zhang","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.tube.2010.03.005_bib18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1099\/0022-1317-51-1-42","article-title":"Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide","volume":"51","author":"Zhang","year":"2002","journal-title":"J Med Microbiol"},{"issue":"3","key":"10.1016\/j.tube.2010.03.005_bib19","first-page":"317","article-title":"Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis","volume":"10","author":"Hu","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"10.1016\/j.tube.2010.03.005_bib20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1843.2006.00941.x","article-title":"Antituberculosis drugs and hepatotoxicity","volume":"11","author":"Yew","year":"2006","journal-title":"Respirology"},{"key":"10.1016\/j.tube.2010.03.005_bib21","first-page":"348","article-title":"Pyrazinamide and Isoniazid used in the treatment of pulmonary tuberculosis","volume":"81","author":"Matthews","year":"1960","journal-title":"Am Rev Respir Dis"},{"issue":"5","key":"10.1016\/j.tube.2010.03.005_bib22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1084\/jem.104.5.763","article-title":"The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug","volume":"104","author":"McCune","year":"1956","journal-title":"J Exp Med"},{"key":"10.1016\/j.tube.2010.03.005_bib23","first-page":"727","article-title":"Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months","volume":"115","author":"Hong Kong Chest Service\/British Medical Research Council","year":"1977","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"10.1016\/j.tube.2010.03.005_bib24","first-page":"748","article-title":"Activation of pyrazinamide and nicotinamide in acidic environments in vitro","volume":"70","author":"McDermott","year":"1954","journal-title":"Am Rev Tuberc"},{"key":"10.1016\/j.tube.2010.03.005_bib25","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200210-1125OC","article-title":"Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days","volume":"167","author":"Jindani","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.tube.2010.03.005_bib26","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946\u20131986, with relevant subsequent publications","volume":"3","author":"Fox","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.tube.2010.03.005_bib27","first-page":"461","article-title":"Pyrazinamide susceptibility and amidase activity of tubercle bacilli","volume":"95","author":"Konno","year":"1967","journal-title":"Am Rev Respir Dis"},{"issue":"Pt 12","key":"10.1016\/j.tube.2010.03.005_bib28","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1099\/jmm.0.46129-0","article-title":"Microarray-based pncA genotyping of pyrazinamide-resistant strains of Mycobacterium tuberculosis","volume":"54","author":"Denkin","year":"2005","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.tube.2010.03.005_bib29","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11095-007-9381-6","article-title":"Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin","volume":"25","author":"Fiegel","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.tube.2010.03.005_bib30","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.addr.2006.07.012","article-title":"In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery","volume":"58","author":"Sakagami","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.tube.2010.03.005_bib31","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1128\/AAC.01164-06","article-title":"Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model","volume":"51","author":"Garcia-Contreras","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2010.03.005_bib32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.tube.2003.08.016","article-title":"Direct lung delivery of para-aminosalicylic acid by aerosol particles","volume":"83","author":"Tsapis","year":"2003","journal-title":"Tuberculosis"},{"key":"10.1016\/j.tube.2010.03.005_bib33","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jac\/dkg477","article-title":"Poly(dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis","volume":"52","author":"Pandey","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2010.03.005_bib34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/dkh411","article-title":"Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral\/aerosolized antitubercular drug carriers for treatment of tuberculosis","volume":"54","author":"Sharma","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2010.03.005_bib35","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijantimicag.2005.07.012","article-title":"Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis","volume":"26","author":"Zahoor","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.tube.2010.03.005_bib36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tibtech.2007.09.005","article-title":"Nanoparticles for drug delivery to the lungs","volume":"25","author":"Sung","year":"2007","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.tube.2010.03.005_bib37","doi-asserted-by":"crossref","first-page":"12001","DOI":"10.1073\/pnas.182233999","article-title":"Trojan particles: large porous carriers of nanoparticles for drug delivery","volume":"99","author":"Tsapis","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tube.2010.03.005_bib38","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.addr.2006.07.009","article-title":"Clinical perspectives on pulmonary systemic and macromolecular delivery","volume":"58","author":"Scheuch","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.tube.2010.03.005_bib39","first-page":"1","article-title":"Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases","volume":"3","author":"Smola","year":"2008","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.tube.2010.03.005_bib40","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0168-3659(02)00370-X","article-title":"Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features","volume":"86","author":"Dailey","year":"2003","journal-title":"J Control Release"},{"key":"10.1016\/j.tube.2010.03.005_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2008.02.008","article-title":"Dexamethasone acetate encapsulation into Trojan particles","volume":"128","author":"Gomez-Gaete","year":"2008","journal-title":"J Control Release"},{"key":"10.1016\/j.tube.2010.03.005_bib42","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1002\/jps.20728","article-title":"A\u00a0practical approach to the use of nanoparticles for vaccine delivery","volume":"95","author":"Wendorf","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.tube.2010.03.005_bib43","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s11095-009-9957-4","article-title":"Inhaled drug delivery for tuberculosis therapy","volume":"26","author":"Muttil","year":"2009","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.tube.2010.03.005_bib44","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.tube.2003.07.001","article-title":"Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis","volume":"83","author":"Pandey","year":"2003","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.tube.2010.03.005_bib45","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jac\/dkl369","article-title":"Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig","volume":"58","author":"Garcia-Contreras","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 2","key":"10.1016\/j.tube.2010.03.005_bib46","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1007\/s00436-002-0769-2","article-title":"Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs","volume":"90","author":"Kayser","year":"2003","journal-title":"Parasitol Res"},{"issue":"5\u20136","key":"10.1016\/j.tube.2010.03.005_bib47","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.tube.2005.08.009","article-title":"Oral solid lipid nanoparticle-based antitubercular chemotherapy","volume":"85","author":"Pandey","year":"2005","journal-title":"Tuberculosis (Edinb)"},{"issue":"1\u20132","key":"10.1016\/j.tube.2010.03.005_bib48","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijpharm.2006.09.017","article-title":"Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis","volume":"330","author":"El-Ridy","year":"2007","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.tube.2010.03.005_bib49","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/713840401","article-title":"Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation","volume":"10","author":"Justo","year":"2003","journal-title":"Drug Deliv"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979210000260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979210000260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T02:27:23Z","timestamp":1544581643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979210000260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S1472979210000260"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2010.03.005","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}